Deutsche Bank Ag\ Amylyx Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 570,857 shares of AMLX stock, worth $3.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

570,857

Previous 570,857 -0.0%

Holding current value

$3.61 Million

Previous $2.15 Million 6.13%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $300,205 - $502,195	-185,312 Reduced 24.51%	570,857 $1.08 Million
Q1 2024 Jun 02, 2025	BUY	$2.71 - $19.57 $502,195 - $3.63 Million	185,312 Added 32.46%	756,169 $2.15 Million
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $262,412 - $1.89 Million	-96,831 Reduced 11.35%	756,169 $2.15 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $10 Million - $15.3 Million	828,584 Added 3393.61%	853,000 $12.6 Million
Q3 2023 Nov 09, 2023	SELL	$18.08 - $23.45 $3.02 Million - $3.92 Million	-167,195 Reduced 87.26%	24,416 $447,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $3.36 Million - $5.04 Million	160,291 Added 511.78%	191,611 $4.13 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $259,337 - $383,063	9,359 Added 42.62%	31,320 $918,000
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $207,565 - $273,917	6,977 Added 46.56%	21,961 $811,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $176,507 - $318,228	10,292 Added 219.35%	14,984 $422,000
Q2 2022 Aug 11, 2022	SELL	$6.85 - $19.93 $4,500 - $13,094	-657 Reduced 12.28%	4,692 $90,000
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $68,734 - $175,982	5,349 New	5,349 $69,000

Others Institutions Holding AMLX

# of Institutions

150

Shares Held

72.6M

Call Options Held

148K

Put Options Held

98.7K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $371M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account